IL1A
Interleukin-1 alpha
Also known as: IL-1A, IL1, IL1-ALPHA, IL1A_HUMAN, IL1F1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01583
- Gene
- IL1A
- Ensembl
- ENSG00000115008
- Chromosome
- 2
- Canonical length
- 271 aa
- Protein class
- Cancer-related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters
- Subcellular location
- Cytosol
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine is a pleiotropic cytokine involved in various immune responses, inflammatory processes, and hematopoiesis. This cytokine is produced by monocytes and macrophages as a proprotein, which is proteolytically processed and released in response to cell injury, and thus induces apoptosis. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. It has been suggested that the polymorphism of these genes is associated with rheumatoid arthritis and Alzheimer's disease. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
271 residues, UniProt reviewed canonical sequence.
>P01583|IL1A
1 MAKVPDMFED LKNCYSENEE DSSSIDHLSL NQKSFYHVSY GPLHEGCMDQ SVSLSISETS
61 KTSKLTFKES MVVVATNGKV LKKRRLSLSQ SITDDDLEAI ANDSEEEIIK PRSAPFSFLS
121 NVKYNFMRII KYEFILNDAL NQSIIRANDQ YLTAAALHNL DEAVKFDMGA YKSSKDDAKI
181 TVILRISKTQ LYVTAQDEDQ PVLLKEMPEI PKTITGSETN LLFFWETHGT KNYFTSVAHP
241 NLFIATKQDY WVCLAGGPPS ITDFQILENQ ALocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 24 nTPM
Expression across tissuesHPA
Tissue
- urinary bladder: 24 nTPM
- esophagus: 14 nTPM
- testis: 9.7 nTPM
- tonsil: 8.1 nTPM
- cervix: 4.5 nTPM
- endometrium: 2.3 nTPM
Single-cell type
- urothelial cells: 357 nCPM
- ocular epithelial cells: 299 nCPM
- epididymal basal cells: 228 nCPM
- monocytes: 155 nCPM
- esophageal apical cells: 77 nCPM
- neutrophils: 76 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 2.1 nTPM
- medulla oblongata: 1.7 nTPM
- midbrain: 1.3 nTPM
- pons: 1.2 nTPM
- spinal cord: 1.1 nTPM
- cerebral cortex: 0.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL1A.
Disease | AutoantibodyPubMed
Conditions in which antibodies against IL1A are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for IL1A from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
46 publications
- Prognostic laboratory markers of joint damage in rheumatoid arthritis.
2005 · Ann Rheum Dis · RCR 7 · 267 citations - Autoantibodies to cytokines--friends or foes?
1990 · Immunol Today · RCR 6.1 · 226 citations - Binding of cytokines to pharmaceutically prepared human immunoglobulin.
1993 · J Clin Invest · RCR 3.1 · 117 citations - Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution, and receptor-binding inhibition--higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia).
1991 · J Allergy Clin Immunol · RCR 2.9 · 105 citations - IgG autoantibodies against interleukin 1 alpha in sera of normal individuals.
1989 · Scand J Immunol · RCR 2.8 · 102 citations
Show 20 more of 46 total
- Human anti-interleukin 1 alpha antibodies.
1991 · Immunol Lett · RCR 2.2 · 81 citations - Glomerular interleukin 1 production is dependent on macrophage infiltration in anti-GBM glomerulonephritis.
1991 · Kidney Int · RCR 1.9 · 77 citations - Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera.
1990 · Scand J Immunol · RCR 1.6 · 63 citations - Schnitzler's syndrome: a broader clinical spectrum.
1991 · J Allergy Clin Immunol · RCR 1.5 · 38 citations - Effects of human anti-IL-1 alpha autoantibodies on receptor binding and biological activities of IL-1.
1992 · Cytokine · RCR 1.4 · 50 citations - B cell biology and dysfunction in SLE.
2007 · Bull NYU Hosp Jt Dis · RCR 1.3 · 59 citations - Demonstration of neutralizing autoantibodies against IL-1 alpha in sera from patients with rheumatoid arthritis.
1990 · J Immunol · RCR 1.1 · 47 citations - Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy.
1997 · Blood · RCR 1.1 · 44 citations - Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects.
1991 · Clin Exp Immunol · RCR 1.1 · 39 citations - Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.
2002 · Ann Rheum Dis · RCR 1 · 48 citations - Anti-interleukin-1 alpha autoantibodies in hemodialysis patients.
1991 · Kidney Int · RCR 0.9 · 32 citations - Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans.
1994 · Eur J Clin Invest · RCR 0.9 · 33 citations - Naturally occurring autoantibodies to interleukin-1 alpha, interleukin-6, interleukin-10, and interferon-alpha.
1994 · J Interferon Res · RCR 0.9 · 28 citations - High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study.
1997 · Scand J Immunol · RCR 0.8 · 37 citations - Quantification of leukocyte migration: improvement of a method.
1996 · Immunol Invest · RCR 0.8 · 26 citations - Identification of high-affinity anti-IL-1 alpha autoantibodies in normal human serum as an interfering substance in a sensitive enzyme-linked immunosorbent assay for IL-1 alpha.
1991 · Lymphokine Cytokine Res · RCR 0.7 · 26 citations - Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis.
2001 · J Med Invest · RCR 0.7 · 33 citations - Identification of human IgG autoantibodies specific for IL-10.
1996 · Clin Exp Immunol · RCR 0.6 · 24 citations - Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis.
1996 · J Clin Immunol · RCR 0.6 · 21 citations - Interleukin-6 autoantibodies: possible biological and clinical significance.
1995 · Leukemia · RCR 0.5 · 21 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.31
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.54
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- cellular response to heat
- cellular response to lipopolysaccharide
- connective tissue replacement involved in inflammatory response wound healing
- cytokine-mediated signaling pathway
- ectopic germ cell programmed cell death
- extrinsic apoptotic signaling pathway in absence of ligand
- fever generation
- immune response
- inflammatory response
- intracellular sodium ion homeostasis
- negative regulation of cell population proliferation
- negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
- positive regulation of angiogenesis
- positive regulation of canonical NF-kappaB signal transduction
- positive regulation of cell division
- positive regulation of cytokine production
- positive regulation of gene expression
- positive regulation of immature T cell proliferation in thymus
- positive regulation of interleukin-2 production
- positive regulation of interleukin-6 production
- positive regulation of mitotic nuclear division
- positive regulation of protein secretion
- positive regulation of transcription by RNA polymerase II
- positive regulation of tumor necrosis factor production
- positive regulation of vascular endothelial growth factor production
- regulation of ERK1 and ERK2 cascade
- response to copper ion
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IL1A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL1A as an antibody target. Whether an autoantibody or antibody against IL1A could matter depends on whether native IL1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL1A is annotated as secreted, so native IL1A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IL1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...